Why IBD 50's No. 2 Stock, Travere Therapeutics, Has Doubled In 2025

Group 1 - Travere Therapeutics (TVTX) stock has more than doubled in 2025, indicating strong market performance despite increasing competition for its drug Filspari [1] - Filspari is approved for treating IgA nephropathy (IgAN), a condition characterized by abnormal antibody accumulation in the kidneys, leading to inflammation and damage [1] - Wall Street analysts believe that Travere Therapeutics still has potential for further growth [1] Group 2 - Ligand Pharmaceuticals' shares have surged by 92% this year, driven by investor interest in its unique royalty-based business model [2] - Celcuity's stock has increased by 534% this year, highlighting significant investor enthusiasm in the biotech sector [4] - Novartis has faced challenges as generics impact its heart-failure drug sales, resulting in a mixed performance in the third quarter [4]